Company:  CYTOSORBENTS CORP (CTSO)
Form Type:  4
Filing Date:  8/13/2019 
CIK:  0001175151 
Address:  7 DEER PARK DRIVE, SUITE K 
City, State, Zip:  MONMOUTH JUNCTION, New Jersey 08852 
Telephone:  973-329-8885 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.92  
Change: 
-0.02 (-0.41%)  
Trade Time: 
10:29 AM EST  
Market Cap: 
$158.93M
Trade CTSO now with 

© 2019  
Description of Business
We are a leader in critical care immunotherapy, investigating and commercializing our CytoSorb blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery. Organ failure is the cause of nearly half of all deaths in the intensive care unit ("ICU"), with little to improve clinical outcome. CytoSorb, our flagship product, is approved in the European Union ("EU") as a safe and effective extracorporeal cytokine filter and is designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES